Quince Therapeutics, Inc. (QNCX)
31.32
+0.77
(+2.52%)
USD |
NASDAQ |
Sep 04, 16:00
31.18
-0.14
(-0.43%)
After-Hours: 20:00
Quince Therapeutics Enterprise Value : 59.69M for Sept. 4, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 04, 2026 | 59.69M |
| September 03, 2026 | 58.90M |
| September 02, 2026 | 60.53M |
| September 01, 2026 | 60.49M |
| August 31, 2026 | 60.96M |
| August 28, 2026 | 62.16M |
| August 27, 2026 | 60.89M |
| August 26, 2026 | 59.68M |
| August 25, 2026 | 59.29M |
| August 24, 2026 | 61.88M |
| August 21, 2026 | 62.34M |
| August 20, 2026 | 60.49M |
| August 19, 2026 | 62.99M |
| August 18, 2026 | 61.30M |
| August 17, 2026 | 62.53M |
| August 14, 2026 | 62.45M |
| August 13, 2026 | 60.79M |
| August 12, 2026 | 59.62M |
| August 11, 2026 | 61.12M |
| August 10, 2026 | 59.00M |
| August 07, 2026 | 58.55M |
| August 06, 2026 | 57.88M |
| August 05, 2026 | 57.20M |
| August 04, 2026 | 55.71M |
| August 03, 2026 | 53.22M |
| Date | Value |
|---|---|
| July 31, 2026 | 51.62M |
| July 30, 2026 | 51.25M |
| July 29, 2026 | 50.21M |
| July 28, 2026 | 47.53M |
| July 27, 2026 | 45.99M |
| July 24, 2026 | 45.99M |
| July 23, 2026 | 46.42M |
| July 22, 2026 | 46.69M |
| July 21, 2026 | 46.93M |
| July 20, 2026 | 46.97M |
| July 17, 2026 | 47.03M |
| July 16, 2026 | 46.82M |
| July 15, 2026 | 46.73M |
| July 14, 2026 | 47.45M |
| July 13, 2026 | 45.38M |
| July 10, 2026 | 45.67M |
| July 09, 2026 | 45.62M |
| July 08, 2026 | 45.38M |
| July 07, 2026 | 45.63M |
| July 06, 2026 | 45.10M |
| July 02, 2026 | 45.35M |
| July 01, 2026 | 44.87M |
| June 30, 2026 | 46.33M |
| June 29, 2026 | -5.062M |
| June 26, 2026 | -4.746M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.96B |
| Oncolytics Biotech, Inc. | 101.43M |
| Sangamo Therapeutics, Inc. | 58.44M |
| Sarepta Therapeutics, Inc. | 2.634B |
| Anixa Biosciences, Inc. | 89.39M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -75.49M |
| Total Expenses (Quarterly) | 75.49M |
| EPS Diluted (Quarterly) | -12.31 |
| Earnings Yield | -401.0% |
| Normalized Earnings Yield | -386.71 |